SCYNEXIS SCYX 深 沪
等待开盘 10-10 09:30:00 美东时间
0.7916
+0.015
+1.91%
华盛通- 最 高0.8059
- 今 开0.79
- 成交量 54.48万股
- 最 低 0.74
- 昨 收 0.7768
- 总市值 3088.85万
- 52周最高 1.6046
- 市盈率 静 --
- 换手率 1.40%
- 52周最低 0.66
- 委 比 66.67%
- 总股本 3902.03万
- 历史最高 150.00
- 量 比 1.57
- 振 幅 8.48%
- 历史最低 0.66
- 每 手 1
- 风险率 0.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SCYNEXIS Reports Results From Phase 1 Study Of SCY-247, Second-Gen Triterpenoid Antifungal Under Development For Treatment And Prevention Of Invasive Fungal Infections
No safety concerns or dose limiting toxicities observedSCY-247 was able to achieve target exposures at doses lower than our first-generation fungerpSafety, tolerability, and pharmacokinetic profile support the continued
09-30 20:07
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
SCYNEXIS announced positive Phase 1 results for SCY-247, a second-generation antifungal. The study showed favorable safety, tolerability, and pharmacokinetics, with SCY-247 achieving target exposures at lower doses than the first generation. It was well-tolerated in healthy participants, with no serious adverse events. SCYNEXIS plans to continue developing SCY-247 to address unmet needs in treating invasive fungal infections.
09-30 12:00
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
SCYNEXIS announced six presentations on SCY-247 at the 12th TIMM Congress in Bilbao, Spain, highlighting its potential against resistant Candida and Aspergillus species. Data show SCY-247's strong in vitro activity against multidrug-resistant C. auris, including FKS1 mutants, and no cross-resistance to echinocandins. Preclinical studies demonstrate efficacy in murine models of C. auris and C. glabrata infections. The company plans to report Phase...
09-04 12:30
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
<p>SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company focused on developing innovative medicines to treat drug-resistant infections, announces that its senior leadership team will participate in the H.C. Wainwright 27th Annual Global Conference on Wednesday, September 10, 2025, in New York City. The event will include an in-person presentation from 10:30 a.m. to 11:00 a.m. ET and one-on-one meetings. SCYNEXIS is developing novel antifungal th...
08-25 12:00
SCYNEXIS Q2 EPS $(0.14) Beats $(0.19) Estimate, Sales $1.364M Beat $154.000K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 26.32 percent. This is a 53.33 percent increase over losses of $(0.30) per share from the same
08-14 04:34
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS reported Q2 2025 financial results, including revenue of $1.4M from the GSK License Agreement and a net loss of $6.9M. The company is progressing its Phase 3 MARIO study with GSK, triggering milestone payments despite disputes, and plans to transfer the BREXAFEMME NDA to GSK by year-end. SCYNEXIS anticipates Phase 1 data for SCY-247 in Q3 2025 and ended Q2 with $46.5M in cash, projecting a cash runway into Q4 2026. The company also saw a...
08-13 20:30
SCYNEXIS Holds Annual Meeting, Re-elects Directors
SCYNEXIS ( ($SCYX) ) just unveiled an update. On June 25, 2025, SCYNEXIS, Inc. ...
07-02 04:41
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
SCYNEXIS announced the resumption of patient dosing in its Phase 3 MARIO study for oral ibrexafungerp after the FDA lifted its clinical hold. This restart triggers a $10 million milestone payment from GSK, with an additional $20 million due in six months. Despite the milestone disputes between SCYNEXIS and GSK, patient enrollment has resumed, with nearly 25% of projected patients already enrolled. The study aims to evaluate ibrexafungerp as a ste...
05-28 12:30
SCYNEXIS Faces Challenges Amidst Antifungal Developments
SCYNEXIS Inc ( ($SCYX) ) has released its Q1 earnings. Here is a breakdown of t...
05-20 11:52
